Telephone
61.3.9801.8888
Address
Boronia 45 Wadhurst Drive Melbourne, Victoria (VIC) 3155
Description
IDT Australia Ltd. produces, develops and supplies pharmaceutical products. It is engaged in the provision of research and development and other technical services for the pharmaceutical and allied industries. The company specializes in the post-discovery pharmaceutical life cycle. It also provides services through API manufacturing, new drug development and scale-up, clinical research services, pharmacy services and finished dosage forms to the pharmaceutical industry. IDT Australia was founded by Graeme Leslie Blackman on October 14, 1975 and is headquartered in Melbourne, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.05 - 0.12
Trade Value (12mth)
AU$4,797.00
1 week
-4.55%
1 month
41.89%
YTD
31.25%
1 year
20.69%
All time high
2.87019
EPS 3 yr Growth
329.600%
EBITDA Margin
-126.00%
Operating Cashflow
-$8m
Free Cash Flow Return
-30.90%
ROIC
-33.20%
Interest Coverage
N/A
Quick Ratio
2.10
Shares on Issue (Fully Dilluted)
251m
HALO Sector
Healthcare
Next Company Report Date
27-Aug-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
31 January 22 |
IDT Australia - Change of Auditor
×
IDT Australia - Change of Auditor |
31 January 22 |
Sterile Readiness Agreement Update
×
Sterile Readiness Agreement Update |
30 September 08 |
Notice of Annual General Meeting/Proxy Form
×
Notice of Annual General Meeting/Proxy Form |
30 September 08 |
Annual Report to shareholders
×
Annual Report to shareholders |
30 October 09 |
Managing Director Powerpoint Presentation
×
Managing Director Powerpoint Presentation |
30 June 23 |
Notice of General Meeting/Proxy Form
×
Notice of General Meeting/Proxy Form |
30 June 23 |
Proposed issue of securities - IDT
×
Proposed issue of securities - IDT |
30 August 23 |
FY23 Full year profit results
×
FY23 Full year profit results |
30 August 23 |
FY23 Full year results presentation
×
FY23 Full year results presentation |
30 August 22 |
IDT Australia Appendix 4E 30 June 2022
×
IDT Australia Appendix 4E 30 June 2022 |
30 August 22 |
IDT Australia Appendix 4G 30 June 2022
×
IDT Australia Appendix 4G 30 June 2022 |
30 August 22 |
IDT Australia Corporate Governance Statement
×
IDT Australia Corporate Governance Statement |
30 August 22 |
IDT Australia FY22 Annual Report
×
IDT Australia FY22 Annual Report |
30 August 22 |
IDT Australia Investor Highlights 2022
×
IDT Australia Investor Highlights 2022 |
29 September 09 |
Notice of Annual General Meeting/Proxy Form
×
Notice of Annual General Meeting/Proxy Form |
29 September 09 |
Annual Report to shareholders
×
Annual Report to shareholders |
29 October 10 |
AGM Presentation
×
AGM Presentation |
29 June 23 |
Ordinary Share Cancellations
×
Ordinary Share Cancellations |
29 June 23 |
Notification of cessation of securities - IDT
×
Notification of cessation of securities - IDT |
29 August 23 |
FY23 Appendix 4E and Annual Report
×
FY23 Appendix 4E and Annual Report |
29 August 23 |
FY23 Appendix 4G and Corporate Governance Statement
×
FY23 Appendix 4G and Corporate Governance Statement |
29 August 19 |
Annual Report to shareholders
×
Annual Report to shareholders |
28 September 22 |
Appointment of Company Secretary and acting CFO
×
Appointment of Company Secretary and acting CFO |
28 October 22 |
Interim CEO Contract Extension
×
Interim CEO Contract Extension |
28 October 13 |
Investor Presentation Australia Biotech Invest 2013.
×
Investor Presentation Australia Biotech Invest 2013. |
28 November 22 |
2022 AGM Chairman's Address
×
2022 AGM Chairman's Address |
28 November 22 |
2022 AGM Presentation
×
2022 AGM Presentation |
28 November 22 |
2022 AGM Results of Meeting
×
2022 AGM Results of Meeting |
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.